Acarix, a company specializing in medical devices for the rapid assessment of coronary artery disease (CAD), has announced that its shares are now being traded on the OTCQB Market in the United States under the ticker symbol ACIXF. This new listing complements Acarix's existing presence on the Nasdaq First North Growth Market in Stockholm.
CEO Aamir Mahmood shared that the United States represents Acarix's most crucial commercial market. By trading on the OTCQB, the company aims to attract a broader investor base to participate in its growth journey. This development is significant as it underscores the company's commitment to expanding its footprint in a market with substantial potential for its innovative medical solutions.
Acarix's flagship product, the CADScor System, is a non-invasive device designed to help healthcare providers rule out CAD in patients experiencing chest pain. The system is both CE-approved and FDA DeNovo-cleared, making it a reliable tool in potentially reducing the need for costly and invasive diagnostic procedures. The CADScor System's ability to offer rapid assessment at the point of care can significantly enhance patient outcomes and streamline the diagnostic process.
Recently, Acarix announced a notable reorder of single-use patches for the CADScor System by a primary care clinic in the New Orleans, Louisiana metropolitan area. These patches are essential for the system's operation in evaluating patients suspected of having coronary artery disease. Additionally, the company has received a multi-order for the CADScor System from Saving Grace Concierge, which plans to use it as a diagnostic aid for symptomatic patients in the Oklahoma City and Tulsa metro areas.
Looking forward, Mahmood outlined the company's strategic focus on top-line growth, reimbursement efforts with the Centers for Medicare & Medicaid Services (CMS) and private payers, and initiating clinical trials. He emphasized the CADScor System's potential to save significant healthcare costs, thereby driving commercial success in the US market.
This announcement is important as it highlights Acarix's dedication to expanding its market reach and improving the efficiency of CAD diagnosis. By trading on the OTCQB Market, Acarix is poised to attract more investors and enhance its commercial success in a key market, ultimately benefiting healthcare providers and patients alike.
